2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

621. Lymphomas: Translational: Molecular and Genetic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Pharmacology, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

1733 Genetic alterations in patients with previously untreated mantle cell lymphoma from the phase 3 ECHO trial

Stephen Douglas Smith, MD, Alexey V. Danilov, MD, PhD2, Morgane Cheminant, MD, PhD3, Mats Jerkeman, MD, PhD4, Rachel Kositsky5, Victoria Otero, MD6, Martin Dreyling, MD, PhD7
1 Division of Hematology and Oncology, University of Washington, Seattle, Washington, United States, Fred Hutchinson Cancer Center, Seattle, Washington, United States
2 City of Hope, Duarte, California, United States
3 Service d’Hématologie Adulte, AP-HP, Hôpital Necker-Enfants Malades, F-75015 Paris, France, Université Paris Cité, Inserm UMR1163, Institut Imagine, Laboratory of Hematological Disorders, F-75015 Paris, France
4 Lund University, Lund, Sweden
5 AstraZeneca, Cambridge, Massachusetts, United States
6 AstraZeneca, Gaithersburg, Maryland, United States
7 Medizinische Klinik III, LMU Hospital, Muenchen, Germany

Introduction: Acalabrutinib plus bendamustine-rituximab (ABR) improved progression-free survival (PFS) vs placebo plus BR (PBR) in patients (pts) with untreated mantle cell lymphoma (MCL) in the phase 3 ECHO trial (NCT02972840; Wang, et al. J Clin Oncol. 2025). Herein, we seek to understand the underlying genomic alterations in MCL and explore their association with outcomes in patients with available samples in the ECHO trial.

Methods: Methods for the ECHO study have been previously described (Wang, et al. J Clin Oncol. 2025). For mutational analysis, formalin-fixed paraffin-embedded tumor samples taken at screening from pts who provided samples and gave consent were sequenced on a custom panel containing 700 genes with hematological significance (median depth of 1413X; 227 pts) and low-pass whole-genome sequencing (WGS; median depth of 3.8X; 214 pts). Short variants were called using DRAGEN small variant caller and filtered for a minimum variant allele frequency (VAF) of 5% and occurrence in previously known MCL driver genes. Copy number variants (CNVs) were assessed using low-pass whole-genome sequencing; ichorCNA was used to call copy number for genomic regions previously established in MCL. Alteration frequencies are reported using assay-specific denominators to avoid deflation from missing data (227 pts for short mutations; 214 pts for CNVs; 208 pts with both mutational and CNV calls; 233 total pts). Clinical associations with PFS were assessed with Cox proportional-hazards regression, and associations with progression of disease within 24 months (POD24) were assessed with Fisher’s exact test, with multiple hypothesis correction via the false discovery rate method.

Results: Among 598 randomized pts, 233 had sequencing data available (median time on study at data cutoff of Feb 15, 2025: 60.1 months). Sequenced and non-sequenced pts had similar PFS (sequenced hazard ratio [HR] 0.96, 95% confidence interval [CI] 0.75–1.23, P=0.74), whereas several baseline characteristics differed between sequenced and non-sequenced pts. In mutational analysis of sequenced pts, ATM, KMT2D, and TP53 were the most frequent mutated genes at rates of 52.4%, 25.5%, and 21.1%, respectively. The most common CNVs were del1p21.2 (S1PR1), del11q22.3-23.2 (ATM), and amp3q25-29 (BCL6), appearing in 44.9%, 37.3%, and 36.9% of pts, respectively. Among all mutations and CNVs analyzed, TP53 (mutation rate 21.1%) and TRAF2 (mutation rate 5.3%) were associated with shorter PFS (TP53: HR 1.96, 95% CI 1.27–3.02, adjusted P=0.043; TRAF2: HR 2.87, 95% CI 1.44–5.70, adjusted P=0.043); no other mutations had a significant impact on PFS. TP53 mutations also were associated with higher rates of POD24 (odds ratio 3.54, 95% CI 1.66–7.69, adjusted P=0.02). In an exploratory threshold sensitivity analysis, optimizing the VAF threshold for maximal PFS separation resulted in an optimized minimum VAF cutoff of 2% (HR 2.13, P=0.0004; mutation rate 22.5%) vs our default of a 5% VAF cutoff (HR 1.96, P=0.0023; mutation rate 21.1%). When restricting the analysis to include only frameshift and nonsense variants at 2% VAF, the PFS difference between patients with mutated TP53 (6.2%) and without (93.8%) increased (HR 3.69, P=0.0001). TP53 variants clustered in the protein’s DNA-binding domain. All 7 TP53 frameshift variants with >2% VAF were predicted to result in a protein truncated in the DNA-binding domain. Pts with high-risk MIPI had significantly worse PFS than those at low/intermediate risk (HR 2.37, P<0.0001). After including pts with TP53 mutation in the high-risk MIPI group, the difference in PFS vs low/intermediate-risk MIPI remained significant (HR 2.09, P=0.0002), maintaining prognostic impact.

Conclusions: This exploratory, hypothesis-generating analysis describes the mutational landscape of TP53 and its prognostic role in more detail. TRAF2 mutations were associated with shorter PFS, and TP53 mutations were significantly associated with increased rates of POD24 and shorter PFS. TP53 VAF and predicted protein effect affected PFS prognosis, suggesting that further exploration of TP53 variant characteristics is warranted.

Stephen Douglas Smith, MD: ADC Therapeutics, Astrazeneca, Beigene, Corvus Pharmaceuticals, Enterome, Genentech, Incyte Corporation, Kymera Therapeutics, Loxo Oncology, Pfizer Oncology, Viracta Therapeutics - Research Funding; Enterome - Research Funding; Natera - Consultancy (Includes expert testimony); Beigene - Consultancy (Includes expert testimony); Beigene, Natera - Consultancy (Includes expert testimony)